Eli Lilly removes mevidalen from Alzheimer’s pipeline after it falls short of its internal benchmark
Key Facts
Eli Lilly removed mevidalen, also known by the code LY3154207, from its development pipeline for treating Alzheimer’s symptoms, announcing the decision in its third-quarter results update. A company spokesperson said the program "did not meet our high internal bar for success." The company did not say that the drug had failed a specific clinical endpoint, and it did not publish detailed trial results. This limits what can be inferred about the reasons for the decision or its impact on the drug’s scientific assessment. The program’s withdrawal comes as Lilly continues to invest in neuroscience, with a portfolio that includes an approved Alzheimer’s treatment and other therapies in development.
The trial of mevidalen was a Phase 2 study that began on August 26, 2024. The initial official record estimated enrollment at 300 participants, while Lilly’s trial page showed a completed enrollment target of 304 participants. The page lists the trial period as running from August 26, 2024, to May 11, 2026. The study was designed to assess the drug’s safety and whether it reduced symptoms in people with mild to moderate Alzheimer’s dementia. Its objectives included cognition, daily activities and other symptoms of the disease, but ClinicalTrials.gov does not show published results for the trial so far.
Lilly has not disclosed the detailed data that led it to end the program, or clarified whether the decision covers development of mevidalen for other indications. The company’s reference to its internal bar is therefore not enough to determine whether the issue was related to safety, efficacy or development considerations, or to establish that the drug failed stated clinical objectives. Mevidalen is a positive allosteric modulator of the dopamine D1 receptor, designed to enhance signaling through a receptor associated with cognitive and motor functions. This design provides context for the drug’s mechanism, but does not reveal the outcome of its Alzheimer’s trial. The official record confirms the trial’s design, duration and enrollment size, without publishing clinical results.
The drug has a prior record in neurological disease: in 2021, Lilly said mevidalen did not meet the primary and secondary cognitive endpoints in a separate Phase 2 trial in patients with dementia with Lewy bodies. That result concerns a different trial and disease from the Alzheimer’s study that the company has now removed from its development pipeline. It is therefore background on the drug’s development, not a published result from the current trial. Lilly’s neuroscience portfolio includes Kisunla, an approved Alzheimer’s treatment, alongside other therapies in development in the field. This places the decision to withdraw mevidalen within a broader portfolio, without implying that the company has stopped developing Alzheimer’s treatments.
The decision was announced alongside strong financial results for the company in the third quarter of 2026: revenue rose 39% year over year to $24.4 billion, driven mainly by Mounjaro and Zepbound. Chief Executive David Ricks said revenue growth was tied to broad global demand for the two treatments, the global launch of Foundayo, and expanded U.S. coverage for obesity care. The company raised its 2026 revenue guidance to $91–92 billion, from a previous range of $85–87 billion. The increase in the midpoint of the guidance was $5.5 billion. The financial update reflects the company’s quarterly business performance and annual outlook, while the available data provided no basis for linking its share price movement to the mevidalen decision.